NR4A2 and esophageal squamous cell carcinoma: Thus, we performed a screen using parecoxib, rofecoxib, and celecoxib, and found that only celecoxib obviously downregulated the protein abundance of NR4A2 in ESCC cells in a dose-dependent manner (Fig. 8A).